1. Introduction {#s0005}
===============

Protracted methamphetamine (MA) use is associated with craving, risky behaviour and executive dysfunction ([@bb0110], [@bb0225], [@bb0310]) as well as deficits in self-regulatory control ([@bb0010], [@bb0240]). However, little is known about the structural brain changes associated with psychological interventions and adjuncts to treatment such as working memory (WM) training that together aim to improve neuropsychological deficits in those with MA use ([@bb0045]). The frontostriatal circuitry is associated with WM function ([@bb0045], [@bb0120], [@bb0105], [@bb0130]) and is impaired following MA exposure in prenatally exposed children ([@bb0200]), adolescents ([@bb0215]) and adults ([@bb0240]). MA adult users typically have smaller prefrontal cortex and larger striatal volumes ([@bb0235], [@bb0210]), which may reflect dopamine-related neurotoxicity ([@bb0240]). In line with this, MA use is associated with reduced striatal dopamine transporter (DAT) and receptor availability ([@bb0240], [@bb0015], [@bb0375]). There is also some evidence that molecular alterations in the striatum involving inhibited expression of brain derived neurotrophic factor \[BDNF\] and dopamine D2 receptor levels may occur following MA use ([@bb0340]). Such molecular alterations may present as altered brain volume, which in turn may be associated with difficulties faced by standard psychological interventions to curtail prevailing high rates of attrition and relapse ([@bb0210], [@bb0285], [@bb0270]).

Abstinence from MA acutely increases caudate and putamen and decreases prefrontal cortex volumes in MA dependent individuals ([@bb0235], [@bb0210]), which could be associated with microglial and other neural processes involved in rapid reorganisation prior to neurogenesis ([@bb0250]), and also with the risk of relapse. However, the influence of psychological intervention on brain processes in contrast to abstinence alone may differentially alter brain volume, but this is not yet known. For example, it is not known whether there is larger or smaller volume in the frontostriatal circuitry following treatment to reflect alterations in neurotoxicity, DA transporter (DAT) levels, receptor regulation or reorganisation of regional brain networks. Thus, by examining how psychological intervention and adjunctive WM training (associated with frontostriatal function ([@bb0045], [@bb0120], [@bb0105], [@bb0130])) alters brain volume it might be possible to isolate the neurobiological markers associated with treatment efficacy. Psychological interventions aim to alter neural processes and enhance problem-solving, self-representation and affect regulation. For example, greater prefrontal cortex and lesser limbic activation has been reported following cognitive behavioural therapy treatment for anxiety disorders ([@bb0050]), which are often comorbid with SUD ([@bb0135]). It is pertinent to consider here that the most common factors for relapse and attrition in those who use MA are poor attention and risky decision making ([@bb0090]), which is associated, in part, with dysfunction in the frontostriatal network ([@bb0195]) and concomitantly deficits in WM.

Against this background, our group has recently shown that cognitive training (CT) with a WM task improves self-reported impulsivity and self-regulation in those with MA use ([@bb0055]). To progress this work, here we examine whether the same CT as an adjunct to treatment as usual (TAU) alters brain volume in patients receiving treatment for MA use. Additionally, we aim to examine how brain changes are associated with improvements in impulsivity and self-regulation.

To aid the formulation of our hypotheses we referred to a recent meta-analysis of WM training in both HC and patients with schizophrenia that demonstrated that greater activation incorporating fronto-parietal networks, the DLPFC and anterior cingulate (ACC), as well as the striatum, are associated with neuroplasticity changes ([@bb0205]). Furthermore, CT is consistently reported to improve cognitive function in those with psychosis ([@bb0175]) and attention deficit hyperactivity disorder (ADHD) ([@bb0185], [@bb0320], [@bb0325]), which are highly comorbid with regular MA use ([@bb0135], [@bb0145]) and so CT is relevant for our study population. While the transferability of CT to general cognitive improvement is debated, specific training that targets localised brain regions and functions might be most effective for those with MA dependence ([@bb0170]). Moreover, frontostriatal circuitry, as well as parietal, insula and cerebellar activation is associated with WM function, as demonstrated in a term-based search ("working memory") of the 'neurosynth' database (<http://www.neurosynth.org/analyses/terms/>), yielding over 900 fMRI studies of WM, which additionally aided the formulation of our hypotheses. WM supports the management of distracting internal representations ([@bb0045], [@bb0095]), such as drug craving and attention to drug paraphernalia. Thus, specifically utilising a WM task as an adjunct to treatment has the potential to strengthen neural processes involved in self-regulation in the presence of distractors in those being treated for MA use.

WM training lowers impulsivity in those with substance use disorders ([@bb0045], [@bb0055], [@bb0025]), and improves attention in those with attentional deficits and the general public, with the current leader in the field of attentional deficits being CogMed™ ([@bb0185], [@bb0325]). However, the CogMed™ package was not implemented during this study because it utilises a selection of WM tasks, whereas our task utilises one task, and we considered that it may be more beneficial, manageable within treatment schedules and less anxiety-provoking for the patients to focus on one WM task that activates a specific brain region. For example, in a meta-analysis of 24 functional magnetic resonance imaging (fMRI) studies using the N-back task, the frontostriatal circuitry is typically activated ([@bb0265]), whereas it is not yet entirely clear which distinct brain regions are activated by CogMed. Therefore, for this study we have used our own modified WM training based on the N-back task called 'Curb Your Addiction (C-Ya)'for CT intervention during TAU. Finally, while fMRI studies have demonstrated that WM training alters brain function in the prefrontal cortex corresponding to occupational changes after 6 months in adults with schizophrenia for example ([@bb0330]), with one fMRI study underway in 7 year-old children born preterm using CogMed™ ([@bb0275]), there has been no evidence to date regarding potential structural brain changes associated with WM training in adults who use MA.

Thus, as well as measuring the effects of abstinence during standard psychological intervention on brain volume in patients being treated for MA dependence we have additionally examined the effects of adjunctive CT using an N-back WM task. Our aim was to measure how brain volume is altered by standard psychological TAU, and whether adjunctive CT is associated with additional brain changes. We also explored whether brain changes are related to changes in impulsivity, self-regulation and mood. Thus, against the research background presented above, our hypotheses are that: a) smaller frontal and larger striatal volumes in MA using patients at baseline (e.g. at the beginning of treatment) will correspond with higher impulsivity and lower self-regulation scores; b) by comparison to TAU, the CT group at 4-weeks\' follow-up will have altered frontostriatal volumes corresponding to greater improvements on impulsivity and self-regulation measures.

2. Methods and materials {#s0010}
========================

2.1. Participants {#s0015}
-----------------

66 males between the ages of 18--50 were recruited for the study from January 2013 to September 2014 in Cape Town, South Africa. In-patients had a history of MA use (n = 41) and attended a local rehabilitation clinic. SUD by way of MA use was measured firstly at clinical interview by qualified psychologists, and secondly during the study phase by a qualified psychiatrist who administered the Structured Clinical Interview for Diagnosis (SCID) \[see below\]. Healthy controls (HC, n = 25) were local members of the public matched by age and gender. Selection of the MA use group was conducted via admission lists by clinicians in the second week of admittance to the in-patient facility. Most commonly in-patients were polysubstance users, or other primary substance users such as heroin or cocaine, and so researchers were required to wait for a potential participant whose primary substance of use was MA, identified by the clinical staff. Upon identification of a potential participant, the study was summarized to the patient by the lead clinician based on an information leaflet provided by the research team. Following this a researcher took informed consent and the study procedures commenced. The study for both MA users and HC began with a SCID interview by a qualified clinical researcher to confirm primary drug use, other comorbidities (e.g. anxiety, depression) and smoking status. Participants were excluded from further study procedures at this stage if they did not meet the inclusion/exclusion criteria as described below. The average duration of MA use in our participants prior to admission was 9.69 (s.d. 3.8) years -- although an accurate average amount of drug taking could not be ascertained as most patients did not know exactly when they started consuming MA. All in-patients, while recent users of MA, were abstinent for two weeks (confirmed by clinicians via urine sampling at the clinic) when commencing our study. The MA group at baseline was divided (alternated in the order that they were admitted to the clinic) into two groups by the researcher: those who would receive TAU (n = 17) and those who would additionally to TAU receive a CT WM intervention (n = 24) as described below. At baseline, participants completed a battery of validated psychological questionnaires to determine levels of self-reported impulsivity, self-regulation, anxiety, depression, happiness, desire for MA and feelings of self-control: at the clinic if in the MA group, and at the university research offices if in the HC group. At a 4-week follow-up session the TAU and CT groups repeated the same questionnaire battery.

Of these participants, several were excluded prior to analyses due to failure to meet inclusion/exclusion criteria, inadequate scan quality, participant drop-out prior to follow-up and equipment failure at the scanner to record the log file. See Supplementary CONSORT diagram.

Inclusion/exclusion criteria for the MA group were: a) MA was the primary substance of use; b) no history of alcohol use/dependence, although participants were permitted to have concomitant cannabis/methaquolone use and/or infrequent alcohol use (as determined by clinical screening); c) no current or previous history of psychosis as confirmed by clinical staff at an admission interview and by researcher interview; d) no prescribed medication during the study.

Inclusion/exclusion criteria for the HC group were: a) no history of substance or alcohol use disorder, b) no history of an Axis I DSM-IV psychiatric diagnosis, c) no previous neurological condition.

All participants were required to be fluent in English, to be left-handed and to have a negative HIV diagnosis, as clarified by clinical staff. At the end of their participation, all participants at baseline received R150 (South African currency, approximately equivalent to \$10) in food vouchers and the MA group who completed the 4-week follow-up (e.g. TAU or CT) received an additional R150 food vouchers. The study adhered to guidelines as set out in the Declaration of Helsinki, and was approved locally by the University of Cape Town Human Research Ethics Committee (Ref: 554/2012).

2.2. Clinical setting {#s0020}
---------------------

Patients were recruited from an in-patient rehabilitation clinic in the Cape Town area that houses a maximum of 40 patients (male and female). The programme at the clinic ran over 8 weeks, during which time patients were provided with 6 meals a day up to 3500 cal, consisting of a large meal at breakfast, supper, lunch and 3 snacks. TAU at the clinic involved 1 h sessions (on each weekday) of dialectical behavioural therapy (DBT) for 6 weeks/30 h at the clinic. DBT is a form of cognitive-behavioural therapy with more emphasis on addressing maladaptive affect regulation, and has demonstrated success in treating substance use disorder ([@bb0315]). Typically, DBT provides skills training in a group, during individual therapy, via telephone coaching and as part of a therapist consultation team. There are normally 4 sets of behavioural skills taught during DBT, namely a) mindfulness, b) distress tolerance, c) interpersonal effectiveness and d) emotion regulation. Greater WM capacity is associated with heightened cognitive control and affect regulation and/or suppression ([@bb0045]) and therefore WM training is a useful adjunct to DBT that attempts to improve such skills. Additionally, patients attended daily group sessions, psychotherapy, basic skills development and both physical and leisure activities.

2.3. CT group -- working memory (WM) training using "Curb Your Addiction (C-Ya)"computerized task {#s0025}
-------------------------------------------------------------------------------------------------

In addition to TAU, the CT group received training in a classroom at the clinic, using a computer based WM task called "Curb Your Addiction (C-Ya)" that was developed by the authors with Fontera Digital Works ([www.fontera.com](http://www.fontera.com){#ir0010}). Copies of the software are available upon request (<http://www.drsamanthabrooks.com>). C-Ya is a modified version of the N-back task (the modification being a distracting peripheral mosaic to mimic peripheral distraction in real life), and for the training in the present study we used standard levels 0-back through to 3-back. The N-back task was originally introduced by [@bb0180] and requires a response to a specified target letter as single letters appear on the screen consecutively. In the present study the letter 'X' was the target for '0-back'; the target for '1-back' was when the current letter was the same as the '1 before'; the target for '2-back' was when the current letter was the same as '2 before' and '3 before' for '3-back'. Targets were identified by pressing the space bar on the computer keyboard. During our standard version of the C-Ya task participants begin by completing 30 min of 0-back and they progress the next day on to the consecutively higher level after achieving at least 80% accuracy on the prior level. An 80% threshold was set for our study because in a previous publication that documented the effects of WM training on neural function the highest level of accuracy attained was 80%. Therefore, we decided to use this as a guideline for participant progression through the levels in our study ([@bb0260]). Accuracy was calculated using the following algorithm:

\[1 − ((number of commissions + number of omissions) / total possible correct)\] × 100 ([@bb0230]), where commissions were responses to non-target letters; omissions were failures to respond to a target, and total possible correct were the total target letters.

Participants in this study were required to engage in the task 5 times a week for 4 weeks (maximum 20 sessions). WM accuracy on the first and last CT day before the baseline and follow-up scan respectively was recorded to link WM function to brain volume changes during analyses as described below.

2.4. Questionnaire measures {#s0030}
---------------------------

### 2.4.1. Structured clinical interview for diagnosis of Axis I DSM-IV disorders (SCID-IV, ([@bb0125])-- patient version with psychotic screen, and non-patient version) {#s0035}

We selected patients who were identified by clinical staff to attend an interview with a researcher using the SCID for DSM-IV, which was conducted at the clinic by a qualified research scientist. For the HC group the SCID was conducted at the university research offices. The SCID included screening questions for substance abuse (including alcohol and other drugs), mood, thought, anxiety and general screening questions.

### 2.4.2. Hospital anxiety and depression scale (HADS) {#s0040}

The HADS is a 14-item questionnaire used to assess patients\' levels of anxiety and depression ([@bb0380]). 7 of the items relate to depression, 7 to anxiety. Items are rated on a 4 point scale, with a maximum score of 21 for both anxiety and depression. A score of 0--7 is 'normal', 8--10 is 'borderline' and 11 or higher is considered significant.

### 2.4.3. Barratt impulsivity scale (BIS) {#s0045}

The BIS is a 30-item questionnaire designed to assess an individual\'s impulsiveness ([@bb0280]). Items are scored on a four-point scale (rarely/never, occasionally, often, almost always/always) to give 6 first order factors (attention, motor, self-control, cognitive complexity, perseverance and cognitive instability) and 3-second order factors (attentional, motor and non-planning).

### 2.4.4. Self-Regulation Questionnaire (SRQ) {#s0050}

The SRQ is a 63-item questionnaire designed to assess an individual\'s self-regulatory processes ([@bb0060]), measuring 7 factors of self-regulation: a) receiving relevant information, b) evaluating information and comparing it to norms, c) triggering change, d) searching for options, e) formatting a plan, f) implementing the plan and g) assessing the plan\'s effectiveness. Items are scored on a 5-point scale (strongly disagree, disagree, unsure, agree, strongly agree) and participants are asked to respond based on how well each statement describes them. It has been verified to give good internal consistency and reliability in a sample of young adults ([@bb0070]).

### 2.4.5. Visual analogue scale (VAS) {#s0055}

The VAS is a psychometric response scale, used to assess subjective feelings ([@bb0350]). In this study mood, desire for drug and feelings of self-control were assessed. Participants responded by placing a mark on a horizontal line to indicate their current feelings. The left end point of the line represents low mood, no desire for drug and no feelings of self-control, and the right end point represents high mood, high desire for drug and high feelings of self-control respectively. The position of the mark on the line was measured and transformed into a percentage for analysis purposes.

### 2.4.6. Trail making test (TMT) {#s0060}

The TMT is a paper-based neuropsychological measure of an individual\'s speed of processing, mental flexibility, executive function (e.g. working memory) visual searching and scanning abilities ([@bb0300]). The TMT consists of two parts; TMT-A and TMT-B. TMT-A requires participants to draw a line between 25 numbers evenly distributed on a piece of paper. TMT B instead requires participants to alternatively join numbers with letters (e.g. 1, A, 2, B, 3, C). The time taken to complete the task and the number of errors are recorded. To account for dexterity the results from TMT-A are subtracted from the results of TMT-B to produce a final score. We used this task to examine near transfer effects of WM training during the study.

### 2.4.7. Working memory accuracy {#s0065}

Each participant played Curb Your Addiction ([www.drsamanthabrooks.com](http://www.drsamanthabrooks.com){#ir0020}) for 12 min (alternating between 6 min of 0-back and 6 min of 1-back) to gauge basic competency on the task during the experimental procedures. Commission and omission errors were recorded to a log file and accuracy was calculated according to the algorithm described above.

2.5. MRI data acquisition and pre-processing {#s0070}
--------------------------------------------

For the MRI scans a 1.5 Tesla Siemens Magnetom Allegra scanner with a 4-channel SENSE head coil was used. Subjects were imaged with a sagittal T1 weighted image, with 3.82 ms repetition time (TR), 4.74 ms echo time (ET), 90° flip angle, acquisition matrix size 200 × 200 × 200, 3 mm acquisition voxel size, 36 contiguous slices and slice thickness 3.5 mm. The nifti-converted T1-weighted images were first manually reoriented along the AC-PC plane and examined for adequate scan quality. Two participant scans were excluded for poor quality.

For cross-sectional (HC versus MA baseline) and the longitudinal (repeated measures baseline versus follow-up in the TAU and CT group) analyses, we used the VBM-8 module of the Statistical Parametric Mapping software package SPM (<http://www.fil.ion.ucl.ac.uk/~john/misc/VBMclass10.pdf>). For the cross-sectional analyses, individual T1 images were first aligned to a T1 template in Montreal Neurological Institute (MNI) space and subsequently segmented into grey matter, white matter and cerebro-spinal fluid. The grey matter images were normalized using the diffeomorphic image registration algorithm (DARTEL) ([@bb0005]) and modulated with the nonlinear transformation parameters as computed during the normalization procedures. Subsequent images contain the volume proportion of probabilistically assigned grey matter tissue for each voxel. These grey matter probability maps were visually inspected using the display function in SPM8 and finally smoothed with an 8-mm Gaussian kernel. Note that each image of the regional grey matter volume was corrected for individual brain size as per the VBM8 toolbox pipeline.

For the repeated measures analyses (baseline and follow-up in TAU and CT groups), MRI data processing was performed using the VBM8 longitudinal batch, which has specific preprocessing steps for repeated measures data. These steps are summarized below. Firstly, the follow-up image was registered to the baseline image for each participant in each group (TAU, CT). Secondly, the mean image was calculated from the realigned images for each participant, and this was used as a reference image for the subsequent spatial alignment. Thirdly, the realigned images were corrected for field inhomogeneity in relation to the reference mean image. Fourthly, tissue segmentation was performed in the bias-corrected mean reference image and the bias-corrected realigned images using the default MNI template. Fifthly, DARTEL spatial normalization parameters were estimated using the tissue segments (grey matter and white matter) of the bias-corrected mean reference image. Sixthly, normalization parameters were applied to the tissue segments of the bias-corrected realigned images. Finally, the resulting normalized tissue segments for each time point of each participant were smoothed with an 8-mm Gaussian kernel. To avoid possible edge effects between grey and white matter, all voxels with grey matter values \< 0.1 were excluded using the absolute threshold masking option available in SPM8.

2.6. Statistical analyses {#s0075}
-------------------------

Normal distribution was examined with Shapiro-Wilks test and by examining boxplots. Parametric or non-parametric analyses were applied accordingly. The assumption of homogeneity of variance was assessed using Levene\'s test, and the Welch-Satterthwaite method was used for all measures where equal variances were not assumed in order to adjust the t-score and p-value.

2.7. *t*-Tests with demographic data {#s0080}
------------------------------------

Data analyses were performed using IBM SPSS Software ([www.ibm.com/software/analytics/spss](http://www.ibm.com/software/analytics/spss){#ir0030}) and Bonferroni corrected for multiple comparisons. Demographic data was assessed using *t*-tests and Chi-squared tests of frequency distribution. All questionnaire measures were assessed using student *t*-tests, and for all non-normally distributed data a Mann Whitney non-parametric *t*-test was performed. These were performed between the following groups: HC vs MA baseline, TAU baseline vs CT baseline, HC vs TAU follow-up, HC vs CT follow-up, TAU follow-up vs CT follow-up. Further paired sample *t*-tests were performed on the TAU and CT group between baseline and follow-up to determine the effects of 4 weeks of standard treatment. A Wilcoxon Signed Ranks test was performed on all non-normally distributed data. All measures were Bonferroni corrected according to each individual questionnaire.

2.8. VBM analyses {#s0085}
-----------------

All analyses were deemed significant at the whole brain, cluster threshold Family Wise Error (FWE) level. First, a full factorial 2 × 2 ANCOVA (Group × WM Accuracy) was conducted in the total cohort to examine the main effect of group (HC and MA) and the main effect of WM accuracy (dichotomised by high/low, split by mean of each group). Covariates of no interest were age and depression score (due to its statistically significant difference between the groups). We chose to run the ANCOVA between HC and MA baseline separately, so as to examine baseline differences, and also given that the HC group was only scanned once as a normative comparison group. The next repeated measures ANCOVA was done to examine how TAU and CT alter brain volume in association to baseline MA.

A second full factorial 3 × 2 ANCOVA (Group × WM Accuracy) was conducted in all methamphetamine users to examine the main effect of group (MA, TAU and CT) and main effect of WM accuracy. Covariates of no interest were age and duration of drug taking (there was no significant difference in depression in the MA groups).

Finally, we conducted a 2 × 2 repeated measures ANCOVA to examine the interaction between group (TAU, CT) and timeline (baseline, follow-up).

3. Results {#s0090}
==========

3.1. Demographic data {#s0095}
---------------------

See [Table 1](#t0005){ref-type="table"} for demographic data. There was no significant difference in age between the HC (mean 27.67 years, s.d. 8.714) and total MA group (mean 28.42 years, s.d. 6.129). However, there were significant differences in education (Chi-squared = 48.891, p ≤ 0.001), with the HC group reaching graduate level education and the MA group reaching a highest qualification level of matriculation (e.g. University entrance level). There were also significant differences in ethnicity (Chi-squared = 41.155, p ≤ 0.001), with the HC group being mostly Caucasian, whereas the MA group were predominantly of mixed ancestry. There was no significant difference in age, duration drug taking, education or ethnicity between the baseline and follow-up groups and between the TAU and CT groups. Thus, the baseline MA group was a robust control group to measure any potential differences at follow-up, although we included the HC group for measures related to non-SUD status.

3.2. Questionnaire measures {#s0100}
---------------------------

See [Table 2](#t0010){ref-type="table"} for between group (HC, MA, TAU, CT) differences.

### 3.2.1. HC vs baseline MA group {#s0105}

Significant differences were found between the HC and Baseline MA group for the following measures: the MA group had a higher percentage desire for drug score (*t* = 3.210, p = 0.001, d = 0.73) a higher trail making response time (*t* = 3.296, p = 0.002, d = 0.83) and a higher HADS depression score (*t* = 4.640, p ≤ 0.001, d = 1.16). The MA group also scored higher on the BIS, including the total score (*t* = 4.625, p ≤ 0.001, d = 1.24), BIS motor (*t* = 3.364, p = 0.001, d = 1.02), BIS self-control (*t* = 3.669, p = 0.001, d = 1.02), BIS cognitive complexity (*t* = 3.479, p = 0.001, d = 0.99), BIS perseverance (*t* = 3.310, p = 0.002, d = 0.93), BIS cognitive instability (*t* = 3.465, p = 0.001, d = 1.00), BIS second order attentional (*t* = 3.432, p = 0.001, *t* = 1.00), BIS second order motor (*t* = 4.008, p ≤ 0.001, d = 1.00) and BIS second order non-planning (*t* = 4.119, p ≤ 0.001, d = 1.16). They also had lower self-regulation than the HC group on several subscales of the SRQ, specifically receiving (*t* = 3.439, p = 0.001, d = 0.98), planning (*t* = 6.297, p ≤ 0.001, d = 1.53), implementing (*t* = 3.705, p = 0.001, d = 0.91) and assessing (*t* = 3.901, p ≤ 0.001, d = 0.92).

### 3.2.2. TAU vs. CT at baseline {#s0110}

There were no significant differences in any questionnaire measure between the MA baseline group which became the TAU and CT groups at follow-up.

### 3.2.3. HC vs. TAU follow-up {#s0115}

The TAU group had significantly higher scores compared to the HC group on the total BIS (*t* = 3.881, p = 0.001, d = 1.48), BIS cognitive instability (*t* = 3.948, p = 0.001, d = 1.63) and BIS second order motor (*t* = 3.189, p = 0.003, d = 1.17). The TAU group also scored lower than the HC group on several subscales of the SRQ, including total SRQ (*t* = 3.172, p = 0.004, d = 1.32), SRQ receiving (*t* = 2.907, p = 0.007, d = 1.07), SRQ planning (*t* = 3.662, p = 0.002, d = 1.56) and SRQ assessing (*t* = 3.325, p = 0.002, d = 1.2).

### 3.2.4. HC vs. CT follow-up {#s0120}

The CT group had significantly longer trail making response times compared to the HC group (*t* = 3.260, p = 0.004, d = 1.3). They also scored significantly lower on several subscales of the SRQ, including SRQ evaluating (*t* = 3.533, p = 0.001, d = 1.25) and SRQ searching (*t* = 2.959, p = 0.005, d = 1.04). There were no significant differences on any other measures.

### 3.2.5. Baseline vs. follow-up repeated measures within-group analyses (TAU and CT) {#s0125}

See [Table 3](#t0015){ref-type="table"} for difference between baseline and follow-up measures.

There were no significant differences between baseline and follow-up in the TAU group at the Bonferroni level. In the CT group, however, there were improvements in working memory accuracy (*t* = 4.833, p ≤ 0.001, d = 1.41), self-reported feelings of self-control (*t* = 3.607, p = 0.003, d = 0.98) and HADS depression (*t* = 2.559, p = 0.023, d = 0.85). There were no significant improvements on any other measures.

3.3. VBM analyses {#s0130}
-----------------

See [Table 4a](#t0020){ref-type="table"}, [Table 4b](#t0025){ref-type="table"} for details of all VBM analyses, which were FWE corrected (besides two findings which were significant at the FDR and uncorrected level respectively, but which we deemed were important to mention).

The 2 × 2 ANCOVA examining group (HC and baseline MA) and WM accuracy revealed no significant differences in brain volume.

A 3 × 2 ANCOVA examined interactions and any main effect of patient group (MA, TAU, CT) and of WM accuracy (high, low), correcting for age and duration of drug taking, Family Wise Error (FWE) corrected. See [Fig. 1](#f0005){ref-type="fig"}. An interaction in the bilateral putamen extending to the hippocampus (x = 27/− 15, y = − 16/9, z = 10/− 11; cluster size = 801/1705 voxels; Z statistic = 5.62/5.50; p = 0.001/0.002) and right cerebellum (x = 29, y = − 85/, z = − 33, cluster size = 4172 voxels, Z statistic = 4.64, p \< 0.001) was observed. A main effect of group was observed in the bilateral putamen extending to the hippocampus (x = − 15/27, y = 9/− 16, z = − 11/10, cluster size = 2375/845 voxels, Z statistic = 5.75/5.42, p \< 0.001/0.002) and the right caudate (x = 20, y = 5, z = − 11, cluster size = 1301 voxels, Z statistic = 4.69, p = 0.049), left thalamus (x = − 17, y-15, z = 10, cluster size = 529 voxels, Z statistic = 4.60, p = 0.05), bilateral cerebellum (x = 29/− 36, y = − 85/− 82, z = − 33/− 30, cluster size = 3314/789 voxels, Z statistic = 4.35/3.84, p \< 0.001/0.01) and left occipital lobe (x = − 23, y = − 97, z = − 17, cluster size = 935 voxels, Z statistic = 4.11, p = 0.004). A main effect of WM accuracy was observed (although it was a preliminary finding as it was only significant without FWE correction) in the right dorsolateral prefrontal cortex (DLPFC) (x = 30, y = 56, z = − 20, cluster size = 155 voxels, Z statistic = 4.10, p = 0.001).

Post-hoc *t*-tests (all FWE corrected) revealed that the TAU follow-up group in comparison to baseline MA group had larger volumes in the bilateral putamen extending to the amygdala/hippocampus (x = 27/− 15, y = − 16/9, z = 10/− 11, cluster size = 851/1085 voxels, Z statistic = 5.56/4.72, p = 0.025/0.009), and the left thalamus (x = − 17, y = − 15, z = 10, cluster size = 648 voxels, Z statistic = 4.45, p = 0.036), but no smaller volumes. The CT follow-up group in comparison to the MA baseline group had larger volumes in the bilateral putamen extending to the hippocampus/amygdala (x = 20/− 15, y = 5/9, z = − 11/− 11, cluster size = 2134/3619 voxels, Z statistic = 5.66/4.82, p \< 0.001/\<0.001), right thalamus (x = 21, y = − 18, z = 12, cluster size = 746 voxels, Z statistic = 4.68, p = 0.041) and left cerebellum (x = − 23, y = − 96, z = − 24, cluster size = 3841 voxels, Z statistic = 4.40, p \< 0.001), but also smaller volumes in discretely different areas of the bilateral cerebellum (x = 30/− 36, y = − 85/− 82, z = − 35/− 30, cluster size = 5135/2649 voxels, Z statistic = 4.57/4.34, p \< 0.001/\<0.001).

3.4. WM accuracy (see [Fig. 2](#f0010){ref-type="fig"}) {#s0135}
-------------------------------------------------------

Post-hoc *t*-tests revealed a preliminary finding (significant only when not FWE corrected) for larger brain volume in the right DLPFC in the high versus low WM accuracy condition regardless of group status (x = 30, y = 56, z = − 20, cluster size = 221 voxels, Z statistic = 4.25, p \< 0.001). Further post-hoc *t*-tests revealed that high WM accuracy during the scan, after 4 weeks of TAU compared to baseline MA was associated with smaller bilateral cerebellar volume (x = 51/− 50, y = − 47/− 63, z = − 44/− 47, cluster size = 2789/855 voxels, Z statistic = 4.01/3.90, p \< 0.001/0.025) and larger bilateral putamen volume extending to the amygdala/hippocampus (x = − 35/27, y = − 7/− 16, z = − 3/10, cluster size = 2527/2757 voxels, Z statistic = 6.32/4.51, p \< 0.001). High WM accuracy in those patients who additionally completed WM training was associated with significantly reduced right cerebellum volume (x = 30, y = − 81, z = − 38, cluster size = 776 voxels, Z statistic = 3.87, p = 0.035) and larger left putamen (extending to the amygdala/hippocampus) (x = − 14, y = 6, z = − 14, cluster size = 1727 voxels, Z statistic = 4.61, p = 0.001). Finally, in the CT group only, there is preliminary evidence (significant without FWE correction) that high WM accuracy is associated with larger volume in the right DLPFC (x = 29, y = 57, z = − 18, cluster size = 438 voxels, Z statistic = 4.24, p = 0.023).

A 2 × 2 repeated measures ANCOVA examined interactions and any main effect of patient group (TAU, CT) and of time point (baseline, follow-up) Family Wise Error (FWE) corrected. See [Fig. 3](#f0015){ref-type="fig"} and [Table 4b](#t0025){ref-type="table"}. Significant interactions were found in the bilateral putamen (extending to the amygdala) (x = 24/− 18, y = − 16/9, z = 12/− 9, cluster size = 1319/3129 voxels, Z statistic = 7.22/5.70, p \< 0.001), the left cerebellum (x = − 29, y = − 54, z = − 44, cluster size = 25,009 voxels, Z statistic = 5.75, p \< 0.001) and the right middle frontal gyrus, Brodmann area 6 (x = 30, y = 2, z = 57, cluster size = 585 voxels, Z statistic = 4.93, p = 0.05). A main effect of patient group was observed, in the right middle frontal gyrus (x = 30, y = 0, z = 57, cluster size 923 voxels, Z statistic = 5.20, p = 0.01) and a main effect of time point was observed in the bilateral putamen (x = 24/20/− 18, y = − 16/3/9, z = 12/− 9/− 9, cluster size = 1738/1683/4706 voxels, Z statistic = 7.41/5.17/6.02, p \< 0.001/0.014) and the left cerebellum (x = − 29, y = − 54, z = − 44, cluster size = 30,060 voxels, Z statistic = 6.07, p \< 0.001). Subsequent post-hoc *t*-tests revealed that TAU (regardless of time point) had larger volume than CT in right middle frontal gyrus, Brodmann area 6 (x = 30, y = 0, z = 57, cluster size = 1135 voxels, Z statistic = 5.32, p = 0.021) and left superior frontal gyrus/supplementary motor area (x = − 17, y = − 12, z = 63, cluster size = 1079 voxels, Z statistic = 4.38, p = 0.026). By contrast the CT group (regardless of time point) had larger volume than the TAU group in the left occipital lobe (x = − 6, y = − 88, z = 7, cluster size = 1252 voxels, Z statistic = 4.12, p = 0.013). There was greater volume at baseline compared to follow-up regardless of group, in the left cerebellum (x = − 29, y = − 54, z = − 44, cluster size = 35,738 voxels, Z statistic = 7.23, p \< 0.001) and the bilateral middle frontal gyrus (x = − 6/8, y = 44/69, z = − 9/− 11, cluster size = 1343/2644 voxels, Z statistic = 4.02, p = 0.009/\<0.001). Conversely, in the follow-up time point regardless of group, larger volume compared to baseline was observed in the right putamen extending to the amygdala (x = 24, y = − 16, z = 12, cluster size = 9715 voxels, Z statistic = 7.50, p \< 0.001) and the bilateral cerebellum (x = − 23/6, y = − 102/− 100, z = − 6/− 21, cluster size = 3243/1117 voxels, Z statistic = 4.81/4.31, p \< 0.001/0.023).

In terms of repeated measures group differences, in the TAU group, we observed larger bilateral cerebellar volumes at baseline compared to follow-up (x = − 50/32, y = − 61/− 84, z = − 45/− 35, cluster size = 7875/8478 voxels, Z statistic = 5.56/4.44, p \< 0.001), whereas at the follow-up timepoint compared to baseline the TAU group had larger right putamen volume (x = 26, y = − 15, z = 13, cluster size = 966 voxels, Z statistic = 6.26, p = 0.04).

In the CT group at baseline compared to follow-up, we again observed larger bilateral cerebellar volumes (x = 32/− 51, y = − 85/− 64, z = − 36/− 35, cluster size = 6756/4747 voxels, Z statistic = 4.87/4.57, p \< 0.001). However, in the follow-up versus baseline time point there were more protracted larger volumes in the CT group than were observed in the TAU group, in bilateral putamen (extending to the amygdala/hippocampus) (x = 22/− 16, y = − 18/6, z = 12/− 9, cluster size = 1023/3033 voxels, Z statistic = 5.69/4.90, p = 0.003/\<0.001) and the right caudate (extending to the amygdala/hippocampus) (x = 20, y = 2, z = − 9, cluster size = 1132 voxels, Z statistic = 4.36, p = 0.021). No other volumetric differences were observed.

4. Discussion {#s0140}
=============

This voxel-based morphometry (VBM) study is the first to examine whether 4 weeks of standard psychological intervention with additional adjunctive working memory (WM) training can alter brain volume in male in-patients being treated for methamphetamine (MA) use. Additionally, we sought to link volumetric brain changes to improvements in subjective self-report measures of impulse control, self-regulation and WM accuracy. It must be noted that changes in self-report measures while intriguing may not transfer to actual changes in clinical measures. Nevertheless, after 4 weeks of psychological TAU, MA using males exhibited larger volume in the bilateral putamen (extending to the hippocampus) and reduced left middle temporal gyrus, right post-central gyrus and left insula cortex volume. Further, those who had additional cognitive training (CT) demonstrated more pronounced increases in volume that extended across large areas of the bilateral basal ganglia, as well as reduced bilateral cerebellar volume. While no significant correlations between questionnaire measures of impulsivity, self-regulation and changes in brain volume were observed, greater improvements/normalization in impulsivity and self-regulation scores were found in the CT compared to the TAU group. This may suggest that the brain volumetric differences observed may be attributable to clinical improvements rather than self-reports in the CT group, although there are likely also other variables at play, such as molecular mechanisms and genetic susceptibility associated with impulsivity. Finally, we presented some preliminary evidence that greater WM accuracy at follow-up in the CT group was associated with larger volume in the right middle frontal cortex and orbitofrontal cortex, regions associated with executive functioning, WM ability and impulse control ([@bb0045]). We suggest that with no medications known to improve MA use disorder reliably and no psychological interventions yet able to effectively reduce relapse rates, it is important to explore the neurobiological effects of adjunctive behavioural interventions such as WM training, and so our study provides a useful progression to the field.

A recent meta-analysis of WM training in both HC and patients with schizophrenia demonstrates that greater activation incorporating frontoparietal networks, the DLPFC and anterior cingulate, as well as the striatum, are associated with neuroplasticity changes ([@bb0205]). Additionally, previous studies have shown that cerebellar ([@bb0115]), striatum, lateral prefrontal and frontoparietal grey matter volume alterations are associated with WM capacity ([@bb0305]), and that larger volume in the lateral prefrontal cortex is particularly susceptible to variations in WM capacity ([@bb0295]). Furthermore, training using a WM task has been associated with reductions in frontoparietal network volume ([@bb0335]), although there is some indication that basal ganglia networks are more susceptible to WM training ([@bb0190]). Thus, in line with previous research, we find increases in volume following WM training that are most significant in the basal ganglia, and we show this for the first time in male patients being treated for MA use.

The effects of CT on brain volume may have been confounded by the neurotoxic effects of MA exposure, suggesting that longitudinal studies using CT may be more beneficial to clinical advances. Neurotoxic effects of MA exposure have been shown by animal models to be associated with reductions in dopamine, serotonin and associated dopamine transporter (DAT) systems, as well as greater expression of brain derived neurotrophic factor (BDNF) in frontal, parietal, and basal ganglia areas ([@bb0040]). DAT is reduced in rats exposed to MA for 10 days, particularly in the striatum, orbitofrontal cortex, dorsolateral prefrontal cortex and amygdala, persisting after abstinence ([@bb0150]). Furthermore, animal models have demonstrated that MA exposure impairs spatial learning and memory, ([@bb0035]), but that proactive interference (the tendency to repeat previous responses) to WM can be ameliorated with a dopamine D1 receptor antagonist ([@bb0220]). Additionally, impaired memory in mice that have been exposed to MA is associated with dysfunction in dopamine D1 receptor-extracellular signal-regulated kinase 1/2 (ERK1/2) pathway in the prefrontal cortex, striatum and hippocampus ([@bb0245]). Thus, animal models of MA exposure and concomitant WM deficits consistently report the involvement of disrupted dopamine activity in the frontostriatal neural circuitry, which is associated with WM. It might therefore be useful to study the effects of WM training on neurochemistry in animal models.

Animal studies of WM training support the hypothesis that frontostriatal circuitry changes coincide with learning and memory. For example, volume change in the medial striatum in mice is implicated in spatial WM training ([@bb0290]), and studies have shown epigenetic effects in the dorsal and medial striatum in mice after WM training ([@bb0075]). Additionally, methylation sequences in prefrontal cortex neurons of mice are shown to be susceptible to WM training effects ([@bb0155]). Furthermore, cerebellar volume (which was shown to be reduced following WM training in our human cohort) is associated with plasticity-related volume increases during motor WM learning in mice ([@bb0370]). Similarly, activation of dopaminergic circuits (associated with the basal ganglia in humans) are shown to mediate short and long term memory formation associated with reward reinforcement in *Drosophila melanogaster* ([@bb0365]). Moreover, the role of greater DLPFC activation in delaying the application of recently learned visual information and of concurrently regulating tactile stimuli is demonstrated in a recent study of monkeys completing a uni- and cross-modal visual and haptic perception task ([@bb0355]). Thus, animal models help to understand the observations of volumetric brain differences in patients with MA dependence undergoing CT in our study.

Studies of CT using WM tasks in humans have highlighted that efficiency within neural system operations can be achieved by potentially fostering inherent plasticity processes ([@bb0175], [@bb0330]), particularly in the frontostriatal circuitry ([@bb0140]). This coincides with improved cognitive functioning in people with ADHD; ([@bb0185], [@bb0325]), schizophrenia ([@bb0205]) and some evidence in those with substance use disorder ([@bb0055], [@bb0030], [@bb0360]). For example, computerized WM training has been shown to reduce impulsivity and delay discounting (lowering the preference for immediate over delayed rewards) among stimulant users ([@bb0025]). Additionally, WM tasks have been shown in a meta-analysis to activate DLPFC with reduced activation coinciding with reduced temporal discounting, a measure of impulsivity, in those with stimulant use disorder ([@bb0360]). However, until now there has been no brain imaging studies to show that WM training alters brain volume associated with underlying functional mechanisms, in the frontostriatal circuitry in MA dependent individuals.

It is intriguing to consider findings that abstinence from MA acutely increases striatal volume, and may be a reflection of compensatory cognitions that maintain optimal functioning, greater glial activation or inflammation associated with MA-related injury ([@bb0210], [@bb0015], [@bb0375], [@bb0250], [@bb0165], [@bb0080], [@bb0160]). Although longer term psychological intervention may differentially alter brain volume. It is not yet clear how interventions for MA use alter brain volume, for example, whether there is larger or smaller volume in the frontostriatal circuitry over a period of time to reflect alterations in neurotoxicity, DA transporter levels and receptor regulation or reorganisation of regional brain networks for example. It might be intuitive to expect a reduction in striatal brain volume following TAU or an adjunctive intervention, given that MA users generally exhibit larger striatal grey-matter volume than non-users ([@bb0020]). However, greater striatal activation associated with neuroplasticity changes have been shown after CT ([@bb0055]), which would support our observations here.

Nevertheless, the question remains, what else could underlie our observed increase in basal ganglia volume following WM training in male in-patients being treated for MA use? It might be that repetitive and increasingly difficult training over 4 weeks encourages inherent neural plasticity after the initial involvement of neuronal support systems (e.g. microglia) ([@bb0250]), which forge more efficient communication along the frontostriatal circuitry. This in turn might lead the patient, during DBT treatment, to have better adherence to cognitive strategies while regulating affective (interoceptive) and environmental (exteroceptive) distractors. For example, blunting of negative affect and drug taking prior to treatment may coincide with a maladaptive coping approach that helps a person to limit the recollection of traumatic life experiences. However, the harnessing of daily and increasingly loaded WM training that fosters inherent neural plasticity ([@bb0175], [@bb0330]) associated with larger brain volumes may reflect enhanced basal ganglia connections and better affect regulation. In this vein, recent evidence in humans supports the view that greater brain volume after a course of WM training may be associated with myelination and related microstructural markers that underpin plasticity and improvements in clinical populations ([@bb0065]). However, it is not yet clear that if WM training fosters such neuroplasticity benefits, whether the effects are longer term, and so more longitudinal studies are needed.

Some limitations deserve consideration during the interpretation of our findings. Firstly, we did not observe greater striatal volume in the MA cohort at baseline, as is extensively reported in humans ([@bb0210], [@bb0160], [@bb0100], [@bb0085]). However, our failure to replicate these well-reported findings could be due to our MA cohort being abstinent for at least two weeks at the start of the study and recovering from malnourishment, which can alter regional brain volume ([@bb0345]), due to re-feeding for two weeks. Therefore, neuronal re-wiring due to treatment and re-feeding effects may have already occurred and prevented our replication of greater striatal volume in MA compared to HC at baseline. Furthermore, we did not take measures of cytokines in blood that may differentiate larger brain volume due to neurotoxicity from larger volume due to neuroplasticity. Secondly, we did not contrast the CT group with a control MA group that also spent time on a computer and had regular contact with researchers but that did not receive the WM training intervention. This is pertinent as it could be that regular social interaction with researchers could have led to the volumetric changes we observed. Additionally, the sample was confounded by our inability to gauge an accurate duration of drug use and length of abstinence prior to treatment, although all in-patients were drug free for two weeks from the beginning of the study. Also, we only recruited males since the in-patient facility at the time of our study housed only males, preventing generalization to females. Finally, there was a significant difference in ethnicity and level of education between the HC and MA group, although we accounted for this by conducting analyses with the baseline MA group as the control condition for treatment effect, and also by conducting repeated measures analyses.

In summary, having previously observed that adjunctive WM training improves outcomes compared to TAU in MA using males ([@bb0055]), here we extend our work by investigating the potential involvement of specific brain regions in improved clinical outcomes, and discuss some possible molecular mechanisms associated with the dopaminergic reward circuitry. First, using voxel-based morphometry we demonstrate that daily adjunctive WM training is associated with greater increases in frontostriatal circuitry than is seen in TAU. Second, we report that in the CT group the neural alterations observed are associated with improvements in self-reported affect regulation and reduced impulsivity. While further work is needed to investigate the neurobiological mechanisms and molecular underpinnings responsible for these increases in volume, as well as potential longitudinal transfer, these data are important in buttressing our view that CT may be useful in those being treated for MA use. We further posit that our data provide a clear model of the relevant neurocircuitry that underlies the impact of CT.
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![Interaction in the bilateral striatum and cerebellum.\
Z = axial plane, colour-bar represents the F-statistic. Top row illustrates bilateral cerebellar differences. Bottom row illustrates bilateral putamen differences.](gr1){#f0005}

![High working memory accuracy in the right middle frontal cortex. a) Higher working memory accuracy during the experimental procedure in both the TAU and CT groups compared to baseline MA revealed larger middle frontal cortex volume; b) Larger bilateral basal ganglia volume associated with higher working memory accuracy in the CT \> MA group; c) larger bilateral basal ganglia volume is also observed in the TAU \> MA group but the effects are less significant than in the previous CT \> MA contrast.](gr2){#f0010}

![Repeated measures effects. a) In TAU, baseline \> follow-up there was larger bilateral cerebellar volume; b) in the CT baseline \> follow-up there was also larger bilateral cerebellar volume; c) in the TAU group at follow-up \> baseline there was larger bilateral putamen volume; d) however, in the CT group at follow-up \> baseline there were more significant larger volumes in the bilateral basal ganglia, extending to amygdala/hippocampus.](gr3){#f0015}

###### 

Demographic variables.

Table 1

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Demographic variables               Groups          Statistic\                                                                                        
                                                      (p-value)\                                                                                        
                                                      (d = Cohen\'s effect size)                                                                        
  ----------------------------------- --------------- ---------------------------- --------------- --------------- ------------------------------------ ------------------------------------
  Age (mean, s.d.)                    27.67 (8.714)   28.42 (6.129)                29.00 (6.291)   28.00 (6.132)   0.381 (0.705)                        0.477 (0.636)

  Type of drug taken (%)                                                                                                                                

   Methamphetamine                    --              36 (100)                     15 (100)        21 (100)        --                                   --

   Mandrax/dagga/marijuana/nicotine                   36 (100)                     15 (100)        21 (100)                                             

  Duration drug taking (yrs)          --              9.69 (3.8)                   10.73 (3.955)   8.95 (3.556)    --                                   1.414 (0.166)

  Ethnicity, n (%)                                                                                                 [⁎⁎](#tf0005){ref-type="table-fn"}   [⁎⁎](#tf0005){ref-type="table-fn"}

   Black                              7 (33)          1 (3)                        1 (6.5)         0 (0)           41.155                               2.965

   Mixed-race                         2 (10)          34 (94)                      13 (87)         21 (100)        (\< 0.001)                           (0.227)

   White                              12 (57)         1 (3)                        1 (6.5)         0 (0)                                                

  Education, n (%)                                                                                                 [⁎⁎](#tf0005){ref-type="table-fn"}   [⁎⁎](#tf0005){ref-type="table-fn"}

   No matric                          1 (5)           23 (64)                      9 (60)          14 (67)         48.891                               0.169

   Matric                             1 (5)           13 (36)                      6 (40)          7 (33)          (\< 0.001)                           (0.681)

   Undergraduate                      12 (57)         0                            0               0                                                    

   Honours                            4 (19)          0                            0               0                                                    

   PhD                                3 (14)          0                            0               0                                                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HC = healthy controls; MA = baseline methamphetamine dependent group; TAU = treatment as usual; CT = cognitive training; p-value = probability value; n = number.

Chi-squared test of frequency distribution.

###### 

Neuropsychological variables between groups.

Table 2

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Neuropsychological variables   Groups\                    T statistic\                                                                                                                                                                                                                                                                                                                                                                 
                                 mean (s.d)                 (p-value)\                                                                                                                                                                                                                                                                                                                                                                   
                                                            (d = Cohen\'s effect size)                                                                                                                                                                                                                                                                                                                                                   
  ------------------------------ -------------------------- ---------------------------- ----------------------- ---------------------- ------------------------ ----------------------- --------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- --------------------------------------------------------------- ---------------------------------------------------------------
                                 Healthy control (n = 21)   All baseline MA (n = 36)     Baseline TAU (n = 15)   Baseline CT (n = 21)   Follow-up TAU (n = 13)   Follow-up CT (n = 15)   HC vs. all baseline MA                                          Baseline TAU vs. baseline CT                            HC vs. follow-up TAU                                    HC vs. follow-up CT                                             Follow-up TAU vs. follow-up CT

  Mood (%)                       63.9 (14.1)                57.1 (26.7)                  55.5 (29.1)             58.2 (25.5)            60.1 (24.4)              75.3 (20.4)             1.267 (0.357[⁎](#tf0010){ref-type="table-fn"}) (0.3)            0.285 (0.704[⁎](#tf0010){ref-type="table-fn"})\         0.583 (0.933[⁎](#tf0010){ref-type="table-fn"}) (0.21)   1.864 (0.119[⁎](#tf0010){ref-type="table-fn"}) (0.69)           1.795 (0.142[⁎](#tf0010){ref-type="table-fn"}) (0.71)
                                                                                                                                                                                                                                                         (0.1)                                                                                                                                                                           

  Desire for drug (%)            3.8 (6.7)                  15.3 (19.5)                  13.9 (22.6)             16.3 (17.6)            13.6 (15.8)              9.6 (18.2)              **3.210 (0.001**[⁎](#tf0010){ref-type="table-fn"}**) (0.73)**   0.360 (0.374[⁎](#tf0010){ref-type="table-fn"}) (0.12)   2.109 (0.038[⁎](#tf0010){ref-type="table-fn"}) (0.92)   1.343 (0.491[⁎](#tf0010){ref-type="table-fn"}) (0.47)           0.610 (0.339[⁎](#tf0010){ref-type="table-fn"}) (0.24)

  Feelings of self-control (%)   83.7 (14.2)                71.6 (19.9)                  69.9 (19.5)             72.9 (20.5)            76.7 (19.6)              89.0 (12.7)             **2.433 (0.018) (0.68)**                                        0.429 (0.547[⁎](#tf0010){ref-type="table-fn"}) (0.15)   1.197 (0.240) (0.44)                                    1.149 (0.161[⁎](#tf0010){ref-type="table-fn"}) (0.4)            1.929 (0.098[⁎](#tf0010){ref-type="table-fn"}) (0.79)

  Trail making errors (B-A)      0.5 (0.6)                  0.6 (0.9)                    0.6 (1.0)               0.5 (0.8)              0.2 (0.7)                0.5 (0.9)               0.333 (0.741) (0.13)                                            0.242 (0.811) (0.12)                                    1.153 (0.258) (0.48)                                    0.149 (0.882) (0)                                               0.975 (0.339) (0.38)

  Trail Making RT (B-A)          32.9 (14.9)                58.2 (37.4)                  54.7 (41.3)             61.1 (35.0)            37.8 (31.4)              57.4 (24.4)             **3.296 (0.002) (0.83)**                                        0.452 (0.655) (0.17)                                    0.520 (0.610) (0.22)                                    **3.260 (0.004) (1.3)**                                         1.783 (0.087) (0.73)

  BIS total                      54.5 (8.1)                 67.7 (12.1)                  68.0 (11.4)             67.4 (12.8)            68.0 (11.2)              60.2 (11.2)             **4.625 (\< 0.001) (1.24)**                                     0.122 (0.903) (0.05)                                    **3.881 (0.001) (1.48)**                                1.690 (0.101) (0.62)                                            1.764 (0.091) (0.72)

  BIS attention                  8.9 (2.4)                  10.4 (2.5)                   10.4 (2.7)              10.5 (2.5)             10.0 (3.1)               9.4 (2.6)               **2.247 (0.029) (0.62)**                                        0.024 (0.796[⁎](#tf0010){ref-type="table-fn"}) (0.04)   1.187 (0.244) (0.42)                                    0.605 (0.550) (0.21)                                            0.555 (0.584) (0.22)

  BIS motor                      14.0 (2.9)                 17.2 (4.4)                   17.0 (4.7)              17.4 (4.2)             17.4 (4.0)               15.6 (2.2)              **3.364 (0.001) (0.83)**                                        0.259 (0.797) (0.09)                                    2.916 (0.006) (1.04)                                    1.864 (0.071) (0.62)                                            1.493 (0.147) (0.59)

  BIS self-control               10.5 (2.8)                 13.5 (3.1)                   14.6 (2.6)              12.7 (3.3)             12.4 (3.0)               11.0 (3.6)              **3.669 (0.001) (1.02)**                                        1.839 (0.075) (0.64)                                    1.903 (0.066) (0.68)                                    0.490 (0.628) (0.16)                                            1.096 (0.284) (0.44)

  BIS cognitive complexity       9.3 (2.4)                  11.9 (2.8)                   11.9 (2.8)              12.0 (3.0)             11.6 (3.5)               11.3 (2.3)              **3.479 (0.001) (0.99)**                                        0.085 (0.933) (0.04)                                    2.283 (0.029) (0.83)                                    2.552 (0.016) (0.87)                                            0.257 (0.799) (0.11)

  BIS perseverance               6.7 (1.6)                  8.6 (2.3)                    8.7 (2.4)               8.5 (2.2)              7.9 (2.2)                8.3 (3.3)               **3.310 (0.002) (0.93)**                                        0.268 (0.790) (0.09)                                    1.821 (0.080[⁎](#tf0010){ref-type="table-fn"}) (0.67)   1.771 (0.093) (0.67)                                            0.380 (0.905[⁎](#tf0010){ref-type="table-fn"}) (0.15)

  BIS cognitive instability      5.0 (1.3)                  6.4 (1.5)                    6.4 (1.6)               6.5 (1.6)              7.6 (2.1)                5.1 (1.4)               **3.465 (0.001) (1)**                                           0.171 (0.849[⁎](#tf0010){ref-type="table-fn"}) (0.06)   **3.948 (0.001) (1.63)**                                0.145 (0.658[⁎](#tf0010){ref-type="table-fn"}) (0.08)           **3.787 (0.002**[⁎](#tf0010){ref-type="table-fn"}**) (1.48)**

  BIS 2nd order attentional      13.9 (2.3)                 16.9 (3.4)                   16.8 (3.5)              16.9 (3.5)             17.6 (4.2)               14.5 (3.1)              **3.432 (0.001) (1)**                                           0.105 (0.813[⁎](#tf0010){ref-type="table-fn"}) (0.03)   2.928 (0.009) (1.21)                                    0.675 (0.505) (0.23)                                            2.275 (0.031) (0.88)

  BIS 2nd order motor            20.7 (3.7)                 25.8 (5.9)                   25.7 (6.3)              25.9 (5.8)             25.5 (5.0)               23.9 (4.9)              **4.008 (\< 0.001) (1)**                                        0.089 (0.930) (0.03)                                    **3.189 (0.003) (1.17)**                                2.290 (0.028) (0.78)                                            0.815 (0.423) (0.34)

  BIS 2nd Order Non-planning     19.8 (4.4)                 25.4 (5.2)                   26.5 (4.6)              24.7 (5.6)             24.0 (5.9)               22.4 (5.4)              **4.119 (\< 0.001) (1.16)**                                     1.029 (0.311) (0.36)                                    2.366 (0.024) (0.86)                                    1.589 (0.122) (0.55)                                            0.724 (0.476) (0.29)

  HADS anxiety                   6.5 (2.8)                  7.8 (2.8)                    8.5 (2.0)               7.4 (3.3)              6.4 (2.6)                6.2 (2.2)               1.693 (0.096) (0.47)                                            1.235 (0.125[⁎](#tf0010){ref-type="table-fn"}) (0.4)    0.108 (0.929[⁎](#tf0010){ref-type="table-fn"}) (0.04)   0.346 (0.835[⁎](#tf0010){ref-type="table-fn"}) (0.12)           0.212 (0.980[⁎](#tf0010){ref-type="table-fn"}) (0.76)

  HADS depression                2.4 (2.3)                  5.8 (3.3)                    5.5 (2.5)               6.0 (3.8)              4.3 (3.0)                3.3 (2.7)               **4.640 (\< 0.001) (1.16)**                                     0.419 (0.678) (0.15)                                    2.095 (0.044) (0.76)                                    1.144 (0.261) (0.76)                                            0.908 (0.372) (0.37)

  SRQ total                      239.8 (13.7)               219.9 (27.8)                 214.2 (21.9)            225.7 (32.5)           219.2 (19.4)             241.4 (27.1)            **3.084 (0.004) (0.86)**                                        1.062 (0.299) (0.23)                                    **3.172 (0.004) (1.32)**                                0.195 (0.848) (0.08)                                            2.164 (0.043) (0.97)

  SRQ receiving                  35.4 (4.3)                 30.0 (6.2)                   29.4 (5.6)              30.5 (6.6)             30.85 (4.5)              35.5 (6.6)              **3.439 (0.001) (0.98)**                                        0.494 (0.625) (0.18)                                    **2.907 (0.007) (1.07)**                                0.063 (0.704[⁎](#tf0010){ref-type="table-fn"}) (0.02)           2.121 (0.019[⁎](#tf0010){ref-type="table-fn"}) (0.84)

  SRQ evaluating                 30.2 (3.4)                 28.8 (7.9)                   30.8 (10.9)             27.2 (3.9)             26.2 (4.0)               26.3 (2.9)              0.781 (0.022[⁎](#tf0010){ref-type="table-fn"}) (0.22)           1.353 (0.185) (0.49)                                    3.062 (0.011[⁎](#tf0010){ref-type="table-fn"}) (1.13)   **3.533 (0.001) (1.25)**                                        0.078 (0.938) (0.03)

  SRQ triggering                 32.9 (3.1)                 31.3 (4.2)                   30.9 (3.7)              31.6 (4.6)             31.7 (2.6)               31.4 (3.8)              1.416 (0.163) (0.42)                                            0.474 (0.931[⁎](#tf0010){ref-type="table-fn"}) (0.17)   1.039 (0.308) (0.42)                                    1.219 (0.232) (0.45)                                            0.195 (0.847) (0.09)

  SRQ searching                  35.5 (3.8)                 36.2 (4.9)                   35.6 (4.6)              36.7 (5.2)             35.0 (5.1)               39.4 (3.9)              0.611 (0.544) (0.16)                                            0.651 (0.520) (0.23)                                    0.283 (0.779) (0.12)                                    **2.959 (0.005**[⁎](#tf0010){ref-type="table-fn"}**) (1.04)**   2.508 (0.027[⁎](#tf0010){ref-type="table-fn"}) (1.02)

  SRQ planning                   36.2 (2.3)                 28.6 (6.1)                   27.5 (5.2)              29.4 (6.7)             30.8 (5.0)               33.7 (7.8)              **6.297 (\< 0.001) (1.53)**                                     0.827 (0.383[⁎](#tf0010){ref-type="table-fn"}) (0.32)   **3.662 (0.002) (1.56)**                                1.198 (0.248) (0.48)                                            1.153 (0.259) (0.45)

  SRQ implementing               36.0 (3.0)                 31.5 (5.9)                   30.5 (4.9)              32.2 (6.7)             33.8 (4.8)               35.7 (7.7)              **3.705 (0.001) (0.91)**                                        0.817 (0.420) (0.29)                                    1.639 (0.120[⁎](#tf0010){ref-type="table-fn"}) (0.6)    0.127 (0.950[⁎](#tf0010){ref-type="table-fn"}) (0.06)           0.821 (0.413[⁎](#tf0010){ref-type="table-fn"}) (0.3)

  SRQ assessing                  35.5 (2.8)                 31.1 (5.7)                   30.6 (5.4)              31.5 (6.0)             31.5 (4.3)               33.9 (4.1)              **3.901 (\< 0.001) (0.92)**                                     0.452 (0.654) (0.16)                                    **3.325 (0.002) (1.2)**                                 1.403 (0.160[⁎](#tf0010){ref-type="table-fn"}) (0.48)           1.481 (0.155[⁎](#tf0010){ref-type="table-fn"}) (0.59)

  Accuracy (%)                                                                                                   48.3 (15.7)                                     67.1 (10.4)                                                                                                                                                                                                                                                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HC = healthy controls; MA = baseline methamphetamine dependent group; TAU = treatment as usual; CT = cognitive training; p-value = probability value; n = number; BIS = Barratt impulsivity scale; HADS = hospital anxiety and depression scale; SRQ = self-regulation questionnaire.

Mann-Whitney non-parametric post-hoc *t*-tests were computed due to non-normally distributed data.

###### 

Baseline vs. follow-up repeated measures within MA group (TAU and CT).

Table 3

  -------------------------------------------------------------------------------------------------------------------------------------------------
  Demographic and psychological variables   T statistic\                                        
                                            (p values)\                                         
                                            (d = Cohen\'s effect size)                          
  ----------------------------------------- --------------------------------------------------- ---------------------------------------------------
  Cognitive training accuracy (%)                                                               **4.833**\
                                                                                                **(\< 0.001)**\
                                                                                                **(d** **=** **1.46)**

  Mood (%)                                  0.852\                                              2.205\
                                            (0.311[⁎](#tf0015){ref-type="table-fn"})\           (0.047[⁎](#tf0015){ref-type="table-fn"})\
                                            (d = 0.18)                                          (d = 0.77)

  Desire for drug (%)                       0.078\                                              1.622\
                                            (0.939)\                                            (0.155[⁎](#tf0015){ref-type="table-fn"})\
                                            (d = 0.02)                                          (d = 0.39)

  Feelings of self-control                  1.025\                                              **3.607**\
                                            (0.456[⁎](#tf0015){ref-type="table-fn"})\           **(0.003**[⁎](#tf0015){ref-type="table-fn"}**)**\
                                            (d = 0.36)                                          **(d** **=** **0.98)**

  Trail making errors (B-A)                 1.915\                                              0.318\
                                            (0.082)\                                            (0.758)\
                                            (d = 0.48)                                          (d = 0)

  Trail making RT (B-A)                     2.403\                                              0.257\
                                            (0.033)\                                            (0.803)\
                                            (d = 0.48)                                          (d = 0.13)

  BIS total                                 0.781\                                              2.872\
                                            (0.458)\                                            (0.013)\
                                            (d = 0)                                             (d = 0.62)

  BIS attention                             **0.356**\                                          1.927\
                                            **(0.002**[⁎](#tf0015){ref-type="table-fn"}**)**\   (0.099[⁎](#tf0015){ref-type="table-fn"})\
                                            **(d** **=** **0.14)**                              (d = 0.45)

  BIS motor                                 0.000\                                              1.822\
                                            (1.000)\                                            (d = 0.092)\
                                            (d = 0.1)                                           (d = 0.56)

  BIS self-control                          2.332\                                              2.071\
                                            (0.038)\                                            (0.059)\
                                            (d = 0.82)                                          (d = 0.51)

  BIS cognitive complexity                  0.090\                                              0.633\
                                            (0.930)\                                            (0.538)\
                                            (d = 0.1)                                           (d = 0.27)

  BIS perseverance                          1.340\                                              0.438\
                                            (0.179[⁎](#tf0015){ref-type="table-fn"})\           (0.669)\
                                            (d = 0.36)                                          (d = 0.07)

  BIS cognitive instability                 2.028\                                              2.259\
                                            (0.067)\                                            (0.046[⁎](#tf0015){ref-type="table-fn"})\
                                            (d = 0.67)                                          (d = 0.96)

  BIS 2nd order attentional                 0.285\                                              2.439\
                                            (0.781)\                                            (0.045[⁎](#tf0015){ref-type="table-fn"})\
                                            (d = 0.34)                                          (d = 0.75)

  BIS 2nd order motor                       0.493\                                              1.558\
                                            (0.632)\                                            (0.143)\
                                            (d = 0.04)                                          (d = 0.39)

  BIS 2nd order non-planning                1.700\                                              1.750\
                                            (0.115)\                                            (0.104)\
                                            (d = 0.49)                                          (d = 0.43)

  HADS anxiety                              1.758\                                              1.046\
                                            (0.105[⁎](#tf0015){ref-type="table-fn"})\           (0.344[⁎](#tf0015){ref-type="table-fn"})\
                                            (d = 0.94)                                          (d = 0.44)

  HADS depression                           1.385\                                              **2.559**\
                                            (0.194)\                                            **(0.023)**\
                                            (d = 0.45)                                          **(d** **=** **0.85)**

  SRQ total                                 0.121\                                              1.794\
                                            (0.907)\                                            (0.116)\
                                            (d = 0.25)                                          (d = 0.54)

  SRQ receiving                             1.044\                                              2.066\
                                            (0.317)\                                            (0.068[⁎](#tf0015){ref-type="table-fn"})\
                                            (d = 0.3)                                           (d = 0.78)

  SRQ evaluating                            1.705\                                              0.351\
                                            (0.114)\                                            (0.732)\
                                            (d = 0.58)                                          (d = 0.27)

  SRQ triggering                            0.559\                                              0.311\
                                            (0.475)\                                            (0.761)\
                                            (d = 0.26)                                          (d = 0.05)

  SRQ searching                             1.424\                                              2.302\
                                            (0.185)\                                            (0.059[⁎](#tf0015){ref-type="table-fn"})\
                                            (d = 0.13)                                          (d = 0.61)

  SRQ planning                              2.709\                                              2.096\
                                            (0.022)\                                            (0.078[⁎](#tf0015){ref-type="table-fn"})\
                                            (d = 0.67)                                          (d = 0.61)

  SRQ implementing                          2.598\                                              1.981\
                                            (0.023[⁎](#tf0015){ref-type="table-fn"})\           (0.061[⁎](#tf0015){ref-type="table-fn"})\
                                            (d = 0.71)                                          (d = 0.5)

  SRQ assessing                             0.386\                                              1.609\
                                            (0.707)\                                            (0.194[⁎](#tf0015){ref-type="table-fn"})\
                                            (d = 0.19)                                          (d = 0.48)
  -------------------------------------------------------------------------------------------------------------------------------------------------

HC = healthy controls; MA = baseline methamphetamine dependent group; TAU = treatment as usual; CT = cognitive training; p-value = probability value; n = number; BIS = Barratt impulsivity scale; HADS = hospital anxiety and depression scale; SRQ = self-regulation questionnaire;

Wilcoxon Signed Ranks non parametric post-hoc *t*-tests were computed due to non-normally distributed data.

###### 

3 × 2 ANCOVA group (MA, TAU and CT) × working memory accuracy (high, low), with age and duration drug taking as covariates of no interest.

Table 4a

  Brain region                                                 MNI coordinates                                
  ------------------------------------------------------------ ----------------- ------- ------ ------ ------ ----------
  Interaction                                                                                                 
  Right putamen (extending to the amygdala/hippocampus)        27                − 16    10     457    5.73   0.001
  Left putamen (extending to the amygdala/hippocampus)         − 18              11      − 9    880    5.21   0.004
  Right cerebellum                                             30                − 85    − 35   6111   5.04   0.009
  Left cerebellum                                              − 29              − 54    − 44   3560   4.96   0.013
                                                                                                              
  Main effect of group                                                                                        
  Right putamen (extending to the amygdala/hippocampus)        27                − 16    10     487    5.61   0.001
  Left putamen (extending to the amygdala/hippocampus)         − 18              11      − 9    1415   5.46   0.001
  Left cerebellum                                              − 29              − 54    − 44   3912   5.02   0.010
  Right cerebellum                                             30                − 85    − 35   6023   4.96   0.012
                                                                                                              
  Main effect of working memory accuracy                                                                      
  Right orbitofrontal cortex (Brodmann area 11)                30                56      − 21   54     3.63   0.001
                                                                                                              
  MA ≥ TAU                                                                                                    
  Mid orbitofrontal cortex (Brodmann area 11)                  − 2               66      − 11   1221   4.07   0.02
  Right cerebellum                                             21                − 87    − 30   1592   3.99   0.007
  MA ≥ CT                                                                                                     
  Right cerebellum                                             30                − 85    − 35   7516   5.06   \< 0.001
  Left cerebellum                                              − 36              − 82    − 30   6056   4.81   \< 0.001
  Left orbitofrontal cortex (Brodmann area 11)                 − 29              63      3      3701   4.27   \< 0.001
                                                                                                              
  TAU ≥ MA                                                                                                    
  Right putamen                                                27                − 16    10     510    5.73   \< 0.001
  Left putamen                                                 − 18              9       − 9    713    4.58   0.05
                                                                                                              
  CT ≥ MA                                                                                                     
  Left putamen (extending to the amygdala/hippocampus)         − 18              11      − 9    1867   5.26   0.003
  Right Thalamus (extending to the amygdala/hippocampus)       21                − 18    10     376    4.76   0.02
  Left Thalamus (extending to the amygdala/hippocampus)        − 15              − 15    7      1278   4.12   0.02
  Right putamen (extending to the amygdala/hippocampus)        21                6       − 9    1227   4.62   0.02
  Left cerebellum                                              − 21              − 97    − 24   929    4.32   0.05
  Right cerebellum                                             8                 − 102   − 6    1053   4.12   0.03
                                                                                                              
  CT ≥ TAU                                                                                                    
  Left midfrontal gyrus (Brodmann area 6)                      − 24              9       43     206    4.29   \< 0.001
                                                                                                              
  High working memory accuracy ≥ low working memory accuracy                                                  
  Right orbitofrontal cortex (Brodmann area 11)                30                56      − 21   90     3.81   \< 0.001
                                                                                                              
  High accuracy MA ≥ TAU                                                                                      
  Left cerebellum                                              − 50              − 63    − 47   1150   3.97   0.03
  Right cerebellum                                             42                − 75    − 42   3288   3.90   \< 0.001
                                                                                                              
  High accuracy MA ≥ CT                                                                                       
  Right cerebellum                                             30                − 81    − 38   1998   3.92   0.002
                                                                                                              
  High accuracy TAU ≥ MA                                                                                      
  Right putamen (extending to the amygdala/hippocampus)        27                − 16    10     1845   6.26   0.003
  Left putamen (extending to the amygdala/hippocampus)         − 20              11      − 6    1565   4.47   0.007
                                                                                                              
  CT high ≥ low accuracy                                                                                      
  Right orbitofrontal cortex (Brodmann area 11)                29                57      − 18   438    4.24   0.023

MNI = Montreal Neurological Institute; FWE = family wise error; TAU = treatment as usual; CT = cognitive training; MA = methamphetamine baseline;

###### 

2 × 2 ANCOVA group (TAU v CT) and time point (baseline, follow-up).

Table 4b

  Brain region                                            MNI coordinates                                  
  ------------------------------------------------------- ----------------- ------- ------ -------- ------ ----------
  Interaction                                                                                              
  Right putamen (extending to the amygdala)               24                − 16    12     1319     7.22   \< 0.001
  Left cerebellum                                         − 29              − 54    − 44   25,009   5.75   \< 0.001
  Left putamen (extending to the amygdala)                − 18              9       − 9    3129     5.70   \< 0.001
  Right middle frontal gyrus (Brodmann area 6)            30                2       57     585      4.93   0.05
                                                                                                           
  Main effect of group                                                                                     
  Right middle frontal gyrus (Brodmann area 6)            30                0       57     923      5.20   0.01
                                                                                                           
  Main effect of time point                                                                                
  Right putamen (extending to the amygdala)               24                − 16    12     1738     7.41   \< 0.001
  Left cerebellum                                         − 29              − 54    − 44   30,060   6.07   \< 0.001
  Left putamen (extending to the amygdala)                − 18              9       − 9    4706     6.02   \< 0.001
  Right putamen (extending to the amygdala)               20                3       − 9    1683     5.17   0.014
                                                                                                           
  TAU ≥ CT (regardless of timepoint)                                                                       
  Right middle frontal gyrus (Brodmann area 6)            30                0       57     1135     5.32   0.021
  Left superior frontal gyrus/SMA (Brodmann area 6)       − 17              − 12    63     1079     4.38   0.026
                                                                                                           
  CT ≥ TAU (regardless of timepoint)                                                                       
  Left occipital lobe (Brodmann area 18)                  − 6               − 88    7      1252     4.12   0.013
                                                                                                           
  Baseline ≥ follow-up (regardless of group)                                                               
  Left cerebellum                                         − 29              − 54    − 44   35,738   7.23   \< 0.001
  Left middle frontal gyrus (Brodmann area 6)             − 6               44      − 9    1343     4.02   0.009
  Right middle frontal gyrus (Brodmann area 6)            8                 69      − 11   2644     4.02   \< 0.001
                                                                                                           
  Follow-up ≥ baseline (regardless of group)                                                               
  Right putamen (extending to the amygdala)               24                − 16    12     9715     7.50   \< 0.001
  Right cerebellum                                        6                 − 102   − 6    3243     4.81   \< 0.001
  Left cerebellum                                         − 23              − 100   − 21   1117     4.31   0.023
                                                                                                           
  TAU: baseline ≥ follow-up                                                                                
  Left cerebellum                                         − 50              − 61    − 45   7875     5.56   \< 0.001
  Right cerebellum                                        32                − 84    − 35   8478     4.44   \< 0.001
                                                                                                           
  TAU: follow-up ≥ baseline                                                                                
  Right putamen                                           26                − 15    13     966      6.26   0.04
                                                                                                           
  CT: baseline ≥ follow-up                                                                                 
  Right cerebellum                                        32                − 85    − 36   6756     4.87   \< 0.001
  Left cerebellum                                         − 51              − 64    − 35   4747     4.57   \< 0.001
                                                                                                           
  CT: follow-up ≥ baseline                                                                                 
  Right putamen (extending to the amygdala/hippocampus)   22                − 18    12     1023     5.69   0.003
  Left putamen (extending to the amygdala/hippocampus)    − 16              6       − 9    3033     4.90   \< 0.001
  Right caudate (extending to the amygdala/hippocampus)   20                2       − 9    1132     4.36   0.021
                                                                                                           
  Baseline: TAU ≥ CT                                                                                       
  No significant volume difference                                                                         
                                                                                                           
  Baseline: CT ≥ TAU                                                                                       
  No significant volume difference                                                                         
                                                                                                           
  Follow-up: TAU ≥ CT                                                                                      
  No significant volume difference                                                                         
                                                                                                           
  Follow-up: CT ≥ TAU                                                                                      
  No significant volume difference                                                                         

MNI = Montreal Neurological Institute; FWE = family wise error; TAU = treatment as usual; CT = cognitive training; SMA = supplementary motor area.
